News
| 4 min read
Generic and biosimilar competition is poised to disrupt billions in annual drug sales, reshaping market dynamics for some of the industry’s most important medicines.
| 4 min read
Emerging clinical trials suggest that the gut microbiome plays a decisive role in how patients respond to immunotherapy.
| 4 min read
Live-cell assays quantify the genetic and metabolic influence on drug selectivity, enabling the development of more precise cancer therapies.
| 4 min read
Alzheimer's disease blood tests, FDA rejections, and more led the news this week.
| 5 min read
A new model combines high-resolution experimental data with deep learning to reveal how non-coding DNA sequences control gene activity across different cell types.
| 4 min read
By separating therapeutic neuroplasticity from hallucinations, new psychedelic-inspired molecules could make treatment safer and more accessible.
| 5 min read
By tracking 5hmC in blood, researchers can capture active cancer pathways, identify novel drug targets, and monitor treatment response more efficiently than traditional approaches.
| 5 min read
Researchers identify how levetiracetam keeps neurons from producing harmful amyloid-beta, pointing to new ways to intervene before Alzheimer’s symptoms appear.
| 3 min read
A Phase 1 trial at Keck Medicine of USC is testing whether implanted iPSC-derived neurons can restore dopamine signaling and improve motor function.
| 4 min read
Legal battles, FDA setbacks, billion-dollar bets, and more led the news this week.
| 5 min read
With gene therapy now a clinical reality, innovators are designing delivery systems that can sustain lifelong correction, handle complex genes, and make treatments accessible to more patients.
| 4 min read
Biopharma’s recovery is real, but the data show a sector that now rewards validated biology, late-stage execution, and commercial relevance.
